Résultats financiers

Monalizumab in combination with durvalumab significantly delayed disease progression in AstraZeneca’s randomized Phase 2 COAST study in unresectable, Stage III NSCLC, advancing to Phase 3 Pre-clinical...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Tuesday, November 16, 2021, at 2 p.m. CET / 8 a.m...

First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2 New pre...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 11, 2021 at 3 p.m...

• Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma • Company’s...

Lacutamab granted PRIME designation in Sézary Syndrome by the European Medicines Agency Monalizumab Phase 3 study initiated, triggering $50 million milestone payment Cash position of €163.6 million*...

Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoides Monalizumab Phase 3 study expected to initiate in the second half of 2020...

Cash, cash equivalents and financial assets of the Company amounted to €206.9 million* First patient dosed in avdoralimab (anti-C5aR) Phase II clinical trial in COVID-19 patients with severe pneumonia...

Innate globally expands its capital markets presence with a successful NASDAQ IPO and Global Offering that provided gross proceeds of $79.1 million (€71.5 million*) Monalizumab to advance to a Phase...

Cash, cash equivalents and financial assets of the Company amounted to €215.2 million* $79.1 million (€71.4 million**) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to...